RGS12

Across TCGA pan-cancer cohorts, RGS12 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RGS12 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RGS12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RGS12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where RGS12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.519	1.000	.011	34	view →
CCRCC	DFS	Median	IV	0.908	0.131	.006	21	view →
LSCC	DFS	Quartile	All	0.569	0.885	.007	16	view →
GBM	OS	Quartile	All	0.564	0.268	.021	5	view →
LUAD	DFS	Tertile	All	0.909	0.959	.009	5	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	3	view →
UCEC	DFS	Median	All	0.968	0.860	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RGS12–PDAC (DFS)

Open the PDAC breakdown →